<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00457392</url>
  </required_header>
  <id_info>
    <org_study_id>A6181087</org_study_id>
    <secondary_id>SUN1087</secondary_id>
    <nct_id>NCT00457392</nct_id>
  </id_info>
  <brief_title>A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Controlled Phase 3, Efficacy And Safety Study Of Sunitinib (SU011248) In Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Treated With Erlotinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test whether treatment with erlotinib plus SU011248 is better than erlotinib
      alone in patients with advanced/metastatic lung cancer who have received previous treatment
      with a platinum-based regimen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline to death or 28 days after last dose for the last participant</time_frame>
    <description>Overall survival is the duration from assignment to study medication to death. For participants who are alive, overall survival is censored at the last contact.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Baseline to disease progression or death due to any cause or 28 days after last dose</time_frame>
    <description>Time in weeks from assignment to study medication to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]), or from adverse event (AE) data (where the outcome was &quot;Death&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Objective Response (OR)</measure>
    <time_frame>Baseline to disease progression or discontinuation from study or 28 days after last dose</time_frame>
    <description>Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0. Confirmed response are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as disappearance of all lesions (target and/or non target). PR are those with at least 30% decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DR)</measure>
    <time_frame>Baseline to disease progression or death or discontinuation from study or 28 days after last dose</time_frame>
    <description>Time in weeks from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One-year Survival Probability</measure>
    <time_frame>Baseline until death or until 28 days after last dose for the last participant</time_frame>
    <description>The 1 year survival probability was defined as the probability of survival at one year after the date of the start of the study treatment based on the Kaplan Meier estimate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol 5-Dimension Questionnaire (EQ-5D)- Health State Profile Utility Score</measure>
    <time_frame>Baseline and End of Treatment (EOT) or Withdrawal</time_frame>
    <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (eg, &quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in total score range -0.594 to 1.000; higher score indicates better health state.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">960</enrollment>
  <condition>Carcinoma, Non-Small Cell Lung</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib</intervention_name>
    <description>plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib</intervention_name>
    <description>Sunitinib 37.5 mg daily by oral capsules in a continuous regimen</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib</intervention_name>
    <description>plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo daily by oral capsules in a continuous regimen</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with locally advanced/metastatic non-small cell lung cancer

          -  Prior treatment with no more than 2 chemotherapy regimens including a platinum-based
             regimen

        Exclusion Criteria:

          -  Prior treatment with any receptor tyrosine kinase inhibitors, VEGF inhibitor (with the
             exception of bevacizumab) or other angiogenesis inhibitors

          -  History of or known brain metastases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Florence</city>
        <state>Alabama</state>
        <zip>35630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Muscle Shoals</city>
        <state>Alabama</state>
        <zip>35661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Antioch</city>
        <state>California</state>
        <zip>94531</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505-4866</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0987</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Montebello</city>
        <state>California</state>
        <zip>90640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pleasant Hill</city>
        <state>California</state>
        <zip>94523</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Leandro</city>
        <state>California</state>
        <zip>94578</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fairfield</city>
        <state>Connecticut</state>
        <zip>06824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <zip>34613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cocoa Beach</city>
        <state>Florida</state>
        <zip>32931</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Merritt Island</city>
        <state>Florida</state>
        <zip>32952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rockledge</city>
        <state>Florida</state>
        <zip>32955</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Titusville</city>
        <state>Florida</state>
        <zip>32796</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Illinois</state>
        <zip>60504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Goshen</city>
        <state>Indiana</state>
        <zip>46526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260-2082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Council Bluffs</city>
        <state>Iowa</state>
        <zip>51503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Mississippi</state>
        <zip>39705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Corinth</city>
        <state>Mississippi</state>
        <zip>38834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. Peters</city>
        <state>Missouri</state>
        <zip>63376</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Grapevine</city>
        <state>Texas</state>
        <zip>76051</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bountiful</city>
        <state>Utah</state>
        <zip>84010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sandy</city>
        <state>Utah</state>
        <zip>84094</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>West Valley</city>
        <state>Utah</state>
        <zip>84102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kennewick</city>
        <state>Washington</state>
        <zip>99336</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <state>Capital Federal</state>
        <zip>C1122AAL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Capital Federal</state>
        <zip>C1094AAD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1034ACO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cordoba</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Grimmenstein</city>
        <zip>A-2840</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Linz</city>
        <zip>A-4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>20230-130</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>20231 -050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90840-440</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Barretos</city>
        <state>SP</state>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01308-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Levis</city>
        <state>Quebec</state>
        <zip>G6V 3Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rimouski</city>
        <state>Quebec</state>
        <zip>G5L 5T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Independencia</city>
        <state>Santiago, RM</state>
        <zip>8380456</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Providencia</city>
        <state>Santiago, RM</state>
        <zip>7500921</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>0</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ceske Budejovice</city>
        <zip>370 87</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nova Ves pod Plesi</city>
        <zip>262 04</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ostrava-Poruba</city>
        <zip>708 52</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Praha 8</city>
        <zip>180 81</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pribram V</city>
        <zip>261 95</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tabor</city>
        <zip>390 03</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>401 13</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hilleroed</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Koebenhavn OE</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bad Berka</city>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ebensfeld</city>
        <zip>96250</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gauting</city>
        <zip>82131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Grosshansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Homburg</city>
        <zip>66424</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Heraklion</city>
        <state>Crete</state>
        <zip>71 110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Alexandroupoli</city>
        <zip>68100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kifisia, Athens</city>
        <zip>145 64</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shatin, NT</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tuen Mun,</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>H-1529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Deszk</city>
        <zip>6772</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gyula</city>
        <zip>5703</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Matrahaza</city>
        <zip>H-3233</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zalaegerszeg-Pozva</city>
        <zip>H-8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Catania</city>
        <zip>95122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Grosseto</city>
        <zip>58100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mantova</city>
        <zip>46100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Monza (MI)</city>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Orbassano (TO)</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Roma</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rozzano (MI)</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>120-725</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Enschede</city>
        <state>Ov</state>
        <zip>7513 ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>'s-Hertogenbosch</city>
        <zip>5211 RW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Arnhem</city>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Harderwijk</city>
        <zip>3844 DG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3097 DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kristiansand S</city>
        <zip>4604</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oslo</city>
        <zip>0379</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Stavanger</city>
        <zip>4011</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tromso</city>
        <zip>9038</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Trondheim</city>
        <zip>7030</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lodz</city>
        <zip>93-509</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Opole</city>
        <zip>45-060</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Otwock</city>
        <zip>05-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>01-138</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zielona Gora</city>
        <zip>65-046</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>143423</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St-Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>826 06</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kosice</city>
        <zip>041 90</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kvetnica pri Poprade</city>
        <zip>058 87</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nitra-Zobor</city>
        <zip>949 88</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zilina</city>
        <zip>012 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>La Laguna</city>
        <state>Santa Cruz de Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dos Hermanas</city>
        <state>Sevilla</state>
        <zip>41700</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>La Corua</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Genolier</city>
        <zip>1272</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gwei Shan Township</city>
        <state>Taoyuan County</state>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pathumwan</city>
        <state>Bangkok</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Amphoe Mueang</city>
        <state>Chiang Mai</state>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bebington, Wirral</city>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Derby</city>
        <zip>DE1 2QY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Keighley, West Yorkshire</city>
        <zip>BD20 6TD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Peterborough</city>
        <zip>PE3 6DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rhyl, Denbigshire</city>
        <zip>LL18 5UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Yeovil, Somerset</city>
        <zip>BA21 4AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6181087&amp;StudyName=A%20Study%20In%20Patients%20With%20Non-Small%20Cell%20Lung%20Cancer%20To%20Test%20If%20Erlotinib%20Plus%20SU011248%20Is%20Better%20Than%20Erlotinib%20Alone</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2007</study_first_submitted>
  <study_first_submitted_qc>April 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2007</study_first_posted>
  <results_first_submitted>July 6, 2011</results_first_submitted>
  <results_first_submitted_qc>July 6, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 2, 2011</results_first_posted>
  <last_update_submitted>September 24, 2013</last_update_submitted>
  <last_update_submitted_qc>September 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>sunitinib</keyword>
  <keyword>erlotinib</keyword>
  <keyword>Phase 3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sunitinib + Erlotinib</title>
          <description>Sunitinib capsule administered orally at a dose of 37.5 milligram (mg) daily (continuous regimen) in a 4 week cycle. Erlotinib administered orally at a dose of 150 mg daily.</description>
        </group>
        <group group_id="P2">
          <title>Erlotinib</title>
          <description>Placebo capsule matched to sunitinib administered orally daily (continuous regimen) in a 4 week cycle. Erlotinib 150 mg tablet orally daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="480"/>
                <participants group_id="P2" count="480"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="473"/>
                <participants group_id="P2" count="477"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="480"/>
                <participants group_id="P2" count="480"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Objective Progression or Relapse</title>
              <participants_list>
                <participants group_id="P1" count="229"/>
                <participants group_id="P2" count="296"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="106"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Global Deterioration of Health Status</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized, Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sunitinib + Erlotinib</title>
          <description>Sunitinib capsule administered orally at a dose of 37.5 milligram (mg) daily (continuous regimen) in a 4 week cycle. Erlotinib administered orally at a dose of 150 mg daily.</description>
        </group>
        <group group_id="B2">
          <title>Erlotinib</title>
          <description>Placebo capsule matched to sunitinib administered orally daily (continuous regimen) in a 4 week cycle. Erlotinib 150 mg tablet orally daily.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="480"/>
            <count group_id="B2" value="480"/>
            <count group_id="B3" value="960"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.10" spread="9.97"/>
                    <measurement group_id="B2" value="60.80" spread="9.13"/>
                    <measurement group_id="B3" value="60.90" spread="9.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                    <measurement group_id="B2" value="196"/>
                    <measurement group_id="B3" value="379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="297"/>
                    <measurement group_id="B2" value="284"/>
                    <measurement group_id="B3" value="581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS)</title>
        <description>Overall survival is the duration from assignment to study medication to death. For participants who are alive, overall survival is censored at the last contact.</description>
        <time_frame>Baseline to death or 28 days after last dose for the last participant</time_frame>
        <population>The Full Analysis (FA) set included all participants who were randomized, with study drug assignment designated according to actual randomization, regardless of whether participants received study drug according to the randomization schedule, or received a different drug from that to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib + Erlotinib</title>
            <description>Sunitinib capsule administered orally at a dose of 37.5 milligram (mg) daily (continuous regimen) in a 4 week cycle. Erlotinib administered orally at a dose of 150 mg daily.</description>
          </group>
          <group group_id="O2">
            <title>Erlotinib</title>
            <description>Placebo capsule matched to sunitinib administered orally daily (continuous regimen) in a 4 week cycle. Erlotinib 150 mg tablet orally daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Overall survival is the duration from assignment to study medication to death. For participants who are alive, overall survival is censored at the last contact.</description>
          <population>The Full Analysis (FA) set included all participants who were randomized, with study drug assignment designated according to actual randomization, regardless of whether participants received study drug according to the randomization schedule, or received a different drug from that to which they were randomized.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="480"/>
                <count group_id="O2" value="480"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="8.4" upper_limit="10.2"/>
                    <measurement group_id="O2" value="8.5" lower_limit="7.4" upper_limit="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Differences in OS between treatment arms was analyzed by the 1-sided log rank test, stratified for smoking status (ever versus never), prior bevacizumab therapy (yes versus no) and epidermal growth factor receptor (EGFR) status (positive, versus negative, versus unknown).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1933</p_value>
            <p_value_desc>p-value was not adjusted for multiple comparisons.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.942</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.822</ci_lower_limit>
            <ci_upper_limit>1.079</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-Free Survival (PFS)</title>
        <description>Time in weeks from assignment to study medication to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]), or from adverse event (AE) data (where the outcome was &quot;Death&quot;).</description>
        <time_frame>Baseline to disease progression or death due to any cause or 28 days after last dose</time_frame>
        <population>The FA set included all participants who were randomized, with study drug assignment designated according to actual randomization, regardless of whether participants received study drug according to the randomization schedule, or received a different drug from that to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib + Erlotinib</title>
            <description>Sunitinib capsule administered orally at a dose of 37.5 milligram (mg) daily (continuous regimen) in a 4 week cycle. Erlotinib administered orally at a dose of 150 mg daily.</description>
          </group>
          <group group_id="O2">
            <title>Erlotinib</title>
            <description>Placebo capsule matched to sunitinib administered orally daily (continuous regimen) in a 4 week cycle. Erlotinib 150 mg tablet orally daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS)</title>
          <description>Time in weeks from assignment to study medication to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]), or from adverse event (AE) data (where the outcome was &quot;Death&quot;).</description>
          <population>The FA set included all participants who were randomized, with study drug assignment designated according to actual randomization, regardless of whether participants received study drug according to the randomization schedule, or received a different drug from that to which they were randomized.</population>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="480"/>
                <count group_id="O2" value="480"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" lower_limit="13.1" upper_limit="16.1"/>
                    <measurement group_id="O2" value="8.7" lower_limit="8.3" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Differences in PFS between treatment arms was analyzed by the 1-sided log rank test, stratified for smoking status (ever versus never), prior bevacizumab therapy (yes versus no) and EGFR status (positive, versus negative, versus unknown).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0023</p_value>
            <p_value_desc>No p-value is adjusted for multiple comparisons for PFS.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>One-sided log-rank test with alpha=0.025 was used.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.807</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.695</ci_lower_limit>
            <ci_upper_limit>0.937</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Objective Response (OR)</title>
        <description>Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0. Confirmed response are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as disappearance of all lesions (target and/or non target). PR are those with at least 30% decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.</description>
        <time_frame>Baseline to disease progression or discontinuation from study or 28 days after last dose</time_frame>
        <population>The FA set included all participants who were randomized, with study drug assignment designated according to actual randomization, regardless of whether participants received study drug according to the randomization schedule, or received a different drug from that to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib + Erlotinib</title>
            <description>Sunitinib capsule administered orally at a dose of 37.5 milligram (mg) daily (continuous regimen) in a 4 week cycle. Erlotinib administered orally at a dose of 150 mg daily.</description>
          </group>
          <group group_id="O2">
            <title>Erlotinib</title>
            <description>Placebo capsule matched to sunitinib administered orally daily (continuous regimen) in a 4 week cycle. Erlotinib 150 mg tablet orally daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Objective Response (OR)</title>
          <description>Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0. Confirmed response are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as disappearance of all lesions (target and/or non target). PR are those with at least 30% decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.</description>
          <population>The FA set included all participants who were randomized, with study drug assignment designated according to actual randomization, regardless of whether participants received study drug according to the randomization schedule, or received a different drug from that to which they were randomized.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="480"/>
                <count group_id="O2" value="480"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.60" lower_limit="8.01" upper_limit="13.73"/>
                    <measurement group_id="O2" value="6.90" lower_limit="4.78" upper_limit="9.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The Cochran-Mantel-Haenszel (CMH) test stratified for smoking status (ever versus never), prior bevacizumab therapy (yes versus no) and EGFR status (positive, versus negative, versus unknown) was used to compare ORR between the 2 treatment arms. The relative risk ratio estimator was used to contrast the treatment effects on response rates. A point estimate of relative risk ratio and 2-sided 95% CI was calculated.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0471</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.514</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.002</ci_lower_limit>
            <ci_upper_limit>2.289</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DR)</title>
        <description>Time in weeks from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 7.</description>
        <time_frame>Baseline to disease progression or death or discontinuation from study or 28 days after last dose</time_frame>
        <population>DR was calculated for the subgroup of participants from the FA set, with a confirmed objective tumor response.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib + Erlotinib</title>
            <description>Sunitinib capsule administered orally at a dose of 37.5 milligram (mg) daily (continuous regimen) in a 4 week cycle. Erlotinib administered orally at a dose of 150 mg daily.</description>
          </group>
          <group group_id="O2">
            <title>Erlotinib</title>
            <description>Placebo capsule matched to sunitinib administered orally daily (continuous regimen) in a 4 week cycle. Erlotinib 150 mg tablet orally daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DR)</title>
          <description>Time in weeks from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 7.</description>
          <population>DR was calculated for the subgroup of participants from the FA set, with a confirmed objective tumor response.</population>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.6" lower_limit="31.3" upper_limit="48.9"/>
                    <measurement group_id="O2" value="32.3" lower_limit="24.2" upper_limit="48.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>One-year Survival Probability</title>
        <description>The 1 year survival probability was defined as the probability of survival at one year after the date of the start of the study treatment based on the Kaplan Meier estimate.</description>
        <time_frame>Baseline until death or until 28 days after last dose for the last participant</time_frame>
        <population>The FA set included all participants who were randomized, with study drug assignment designated according to actual randomization, regardless of whether participants received study drug according to the randomization schedule, or received a different drug from that to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib + Erlotinib</title>
            <description>Sunitinib capsule administered orally at a dose of 37.5 milligram (mg) daily (continuous regimen) in a 4 week cycle. Erlotinib administered orally at a dose of 150 mg daily.</description>
          </group>
          <group group_id="O2">
            <title>Erlotinib</title>
            <description>Placebo capsule matched to sunitinib administered orally daily (continuous regimen) in a 4 week cycle. Erlotinib 150 mg tablet orally daily.</description>
          </group>
        </group_list>
        <measure>
          <title>One-year Survival Probability</title>
          <description>The 1 year survival probability was defined as the probability of survival at one year after the date of the start of the study treatment based on the Kaplan Meier estimate.</description>
          <population>The FA set included all participants who were randomized, with study drug assignment designated according to actual randomization, regardless of whether participants received study drug according to the randomization schedule, or received a different drug from that to which they were randomized.</population>
          <units>Percent chance of survival</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="480"/>
                <count group_id="O2" value="480"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0" lower_limit="35.4" upper_limit="44.2"/>
                    <measurement group_id="O2" value="37.0" lower_limit="32.8" upper_limit="41.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EuroQol 5-Dimension Questionnaire (EQ-5D)- Health State Profile Utility Score</title>
        <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (eg, &quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in total score range -0.594 to 1.000; higher score indicates better health state.</description>
        <time_frame>Baseline and End of Treatment (EOT) or Withdrawal</time_frame>
        <population>Patients Reported Outcome (PRO) Analysis Set included participants from the FA population who had at least one EQ-5D assessment while on treatment. The 'n' signifies those participants who received study drug and were evaluated for this measure at the timepoint for each group respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib + Erlotinib</title>
            <description>Sunitinib capsule administered orally at a dose of 37.5 milligram (mg) daily (continuous regimen) in a 4 week cycle. Erlotinib administered orally at a dose of 150 mg daily.</description>
          </group>
          <group group_id="O2">
            <title>Erlotinib</title>
            <description>Placebo capsule matched to sunitinib administered orally daily (continuous regimen) in a 4 week cycle. Erlotinib 150 mg tablet orally daily.</description>
          </group>
        </group_list>
        <measure>
          <title>EuroQol 5-Dimension Questionnaire (EQ-5D)- Health State Profile Utility Score</title>
          <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (eg, &quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in total score range -0.594 to 1.000; higher score indicates better health state.</description>
          <population>Patients Reported Outcome (PRO) Analysis Set included participants from the FA population who had at least one EQ-5D assessment while on treatment. The 'n' signifies those participants who received study drug and were evaluated for this measure at the timepoint for each group respectively.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="451"/>
                <count group_id="O2" value="465"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.750" spread="0.239"/>
                    <measurement group_id="O2" value="0.716" spread="0.263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Treatment (n= 285, 301)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.615" spread="0.348"/>
                    <measurement group_id="O2" value="0.598" spread="0.339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sunitinib + Erlotinib</title>
          <description>Sunitinib capsule administered orally at a dose of 37.5 milligram (mg) daily (continuous regimen) in a 4 week cycle. Erlotinib administered orally at a dose of 150 mg daily.</description>
        </group>
        <group group_id="E2">
          <title>Erlotinib</title>
          <description>Placebo capsule matched to sunitinib administered orally daily (continuous regimen) in a 4 week cycle. Erlotinib 150 mg tablet orally daily.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="207" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="181" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Anaemia of malignant disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Tracheo-oesophageal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Acute abdomen</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Gastric perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Thrombosis mesenteric vessel</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Euthanasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Gallbladder perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pyonephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pyothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>General physical condition abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Osteonecrosis of jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Liposarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Meningorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Neurological decompensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Sopor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Focal segmental glomerulosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pulmonary infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Superior vena caval occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="463" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="461" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Anaemia megaloblastic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Granulocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Haemorrhagic diathesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Macrocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Neutrophilia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Bundle branch block right</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Trichomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Dysacusis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Ear haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Ear pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Motion sickness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Parathyroid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Erythema of eyelid</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Eye allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Eye disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Eye oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Eyelid disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Eyelid function disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Eyelid pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Keratoconjunctivitis sicca</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Lacrimal gland enlargement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Lenticular opacities</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Mydriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Ocular icterus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Ocular surface disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Panophthalmitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Abdominal strangulated hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Abnormal faeces</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Anorectal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Aphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Aptyalism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Breath odour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Chapped lips</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="335" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="188" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Erosive duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Erosive oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Gastritis atrophic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hypermotility</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Gastrointestinal motility disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Gastrointestinal sounds abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Glossitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hyperchlorhydria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Jejunitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Lip blister</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Lip dry</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Lip oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Lip pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Lip ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="114" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Oesophageal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Oral discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Rectal tenesmus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Reflux gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Thrombosis mesenteric vessel</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Tongue haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Tooth deposit</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Tooth discolouration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Tooth disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Tooth loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Axillary pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="128" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hyperpyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Implant site discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Mucosal dryness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Mucous membrane disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Performance status decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Sensation of foreign body</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Vestibulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Xerosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary dilatation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hepatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal wall infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Anal fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Dermatitis infected</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Nail infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Oral fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Oral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Parainfluenzae virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pyothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Skin bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Tinea cruris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Inappropriate schedule of drug administration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Medication error</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Periorbital haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Procedural nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Scratch</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Wound secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Aspiration bronchial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Blood albumin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Blood calcium increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Blood creatine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Blood magnesium decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Blood urea decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Blood uric acid decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Body temperature decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Breath sounds abnormal</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>ECG signs of myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Eastern cooperative oncology group performance status worsened</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Fibrin D dimer increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypophonesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Platelet count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Protein total decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Renal function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Thrombin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Thyroxine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="190" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Food intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypercreatininaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Finger deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypercreatinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Muscle atrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Muscle contracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Muscle disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Musculoskeletal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Osteonecrosis of jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Palmar fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Spondylitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Nasal cavity cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Acrodynia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Ageusia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Anosmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Areflexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Clonus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Coordination abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Dyslalia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Facial neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Facial spasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Horner's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hyperaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypertonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypogeusia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Monoplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Motor dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Muscle contractions involuntary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Petit mal epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Vagus nerve disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Visual field defect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Vocal cord paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Listless</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Sopor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Albuminuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Choluria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Haemoglobinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Renal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Urine flow decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Breast discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Breast oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Genital rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Vulvovaginal pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Choking</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Diaphragmalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="103" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypoventilation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Increased upper airway secretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Nasal dryness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Nasal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Nasal mucosal disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Nasal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Painful respiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pharyngeal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pulmonary artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pulmonary cavitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Rales</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Rhinitis atrophic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Rhonchi</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Sinus disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Sputum discoloured</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Stridor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Dermatitis exfoliative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Exfoliative rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hair colour changes</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hair disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hair growth abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hair texture abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypertrichosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia facial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Intertrigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Leukocytoclastic vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Madarosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Nail bed inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Nail discolouration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Nail discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Onychoclasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Palmar erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Prurigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="277" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="255" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Rash follicular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Rash scarlatiniform</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Rash vesicular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Scab</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Scar pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Skin atrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Skin burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Skin chapped</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Skin discolouration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Skin haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Skin hypopigmentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Skin maceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Skin nodule</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Skin reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Skin toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Subcutaneous emphysema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Trichorrhexis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Xanthoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Xeroderma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Yellow skin</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Skin neoplasm excision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Urethral dilation procedure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Angiodysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Peripheral coldness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Subclavian vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Superior vena caval occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Venous insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="473"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

